Galmed Pharmaceuticals Ltd.

Develops oral therapeutics for liver, metabolic, and inflammatory diseases like NASH.

GLMD | NDAQ

Overview

Corporate Details

ISIN(s):: IL0011313900
LEI:
Country:: United States of America
Address:: C/O MEITAR LAW OFFICES, 5250608 RAMAT GAN
Website:: https://www.galmedpharma.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company that develops oral therapeutics for liver, metabolic, and inflammatory diseases. The company's lead drug candidate, Aramchol, is in late-stage clinical development for the treatment of liver conditions such as Non-alcoholic steatohepatitis (NASH). Galmed focuses on leveraging its understanding of drug research and breakthrough mechanisms of action to deliver effective and safe lifetime medicines. The company's pipeline is highlighted by its ARMOR Phase 3 study for Aramchol, supported by the identification of a proprietary biomarker signature to potentially expand its therapeutic applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Galmed Pharmaceuticals Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Galmed Pharmaceuticals Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Galmed Pharmaceuticals Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Denali Therapeutics Inc. Developing therapies for neurodegenerative diseases that cross the blood-brain barrier.	United States of America	DNLI
Dermapharm Holding SE Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.	Germany	DMP
Dermata Therapeutics, Inc. Develops OTC skin treatments using a unique delivery technology from freshwater sponges.	United States of America	DRMA
Design Therapeutics, Inc. Develops small molecule genomic medicines to treat serious genetic diseases by modulating genes.	United States of America	DSGN
Deutsche Biotech Innovativ AG Develops biomarker-driven therapeutics and diagnostics for serious diseases with unmet needs.	Germany	DBI
DEVA HOLDİNG A.Ş. Global manufacturer of human/veterinary pharmaceuticals, APIs, and medical ampoules.	Spain	DEVA
Devyser Diagnostics Develops & sells genetic DNA test kits for labs in oncology, transplant & reproductive health.	Sweden	DVYSR
DiaMedica Therapeutics Inc. Developing a novel protein therapy for acute ischemic stroke and preeclampsia.	United States of America	DMAC
Diamyd Medical AB (publ) Developing precision immunotherapies to preserve insulin in autoimmune diabetes.	Sweden	DMYD
Dianthus Therapeutics, Inc. /DE/ Developing selective antibody therapies for severe autoimmune diseases.	United States of America	DNTH